Head of the Unit for HemostasisThrombosis and Benign Hematology Disorders, Division of Hematology, Department of Internal Medicine, University Hospital Center ZagrebZagreb, Grad Zagreb, Croatia
LB 01.1 - Safety, tolerability, and efficacy of mezagitamab (TAK-079) in chronic or persistent primary immune thrombocytopenia: Interim results from a phase 2, randomized, double-blind, placebo-controlled study
Sunday, June 23, 202409:30 – 09:45 ICT
